Join us at the 13th Annual WRIB Conference in New Orleans, LA - April 1-5, 2019
Pacific Biomarkers has over a decade of experience offering a full range of bioanalytical services for large molecules coveringImmunogenicity (ADA), Pharmacokinetics (PK), Proprietary Biomarkers, and Cell Based assays. We support studies under GLP, GCP while also maintaining a strong foundation in CAP/CLIA regulations. We are recognized for our scalable operational model resulting in optimal flexibility for our clients and high throughput capabilities for supporting large global studies.
Pacific Biomarkers recently expanded its service offerings with a new site in Montreal (NEOMED-LABS) supporting vaccine development under full GCLP compliance specializing in Immunochemistry and Viral and Bacterial functional assays.
Come by Booth 68 and register to win a fitbit.
The FDA has approved the qualification of the safety biomarker panel to aid in the detection of kidney tubular injury!
The FDA has approved the qualification of the safety biomarker panel to aid in the detection of kidney tubular injury!
Biomarker Panel: KIM-1,cystatin C, NGAL, clusterin, osteopontin and NAG
Context of Use: A safety composite biomarker panel can be used in conjunction with traditional measures to aid in the detection of kidney tubular injury in phase 1 trials in healthy volunteers when there is an a priori concern that a drug may cause renal tubular injury in humans.
All urine biomarker assay analytical and clinical study data were generated at Pacific Biomarkers.
Introducing Ella™
Protein Simple – Ella™ is the latest platform to meet our standards of Performance & Reliability.
- Microfluidics technology
- Extensive menu
- No cross reactivity or carryover
- Exceptional precision
- Reduced hands on time, sample volume, waste and maintenance
Announcing the Appointment of Cheikh Kane, PhD as Director of Bioanalytical Services
Cheikh brings with him 15 years of Immunoassay experience for large molecules. Dr. Kane brings scientific depth, regulatory knowledge, and extensive problem solving skills in the immunogenicity assay development area.
Cheikh Kane, PhD
Director of Bioanalytical Services
Director of Bioanalytical Services
Read our recently published article in the Journal of Applied Laboratory Medicine (JALM):
Impact of Hydrophobic Non-Specific Binding on Assay Recovery for Some Urinary Biomarkers of Acute Kidney Injury. Download PDF
Authors: Candace M. Adamo, Amar A. Sethi, Timothy H. Carlson
Biomarker Menu Search:
Use this tool to search our offerings of over 300+ validated assays.
The Pacific Biomarkers Mobile App, available on the Apple App Store and Google Play!
Download now for phones and tablets from…
Our Mobile App provides access to new innovative tools, such as the Biomarker Navigator™ click below to learn more.
Learn More
Featured Presentation:
Platform comparison study testing multiple ultra-sensitive assay technologies presented by Dr. Maribeth Raines, Ph.D., our Vice President of Laboratory Services at the Biomarker World Congress (May 2016).
Presented by Maribeth Raines, Ph.D.
Download PDFPacific Biomarkers at a Glance
OVER
90%
repeat business from Central Labs and pharma clients
We have supported over
190
drugs in development over the past 5 years
20%
of Pacific Biomarker team members have an MD and/or a PhD.
9 OUT OF 10
Pacific Biomarkers supports 9 of the top-10 pharma clients around the globe.
~300
fully validated biomarkers CAP/CLIA standards
Platforms and Services:
Immunoassay Platforms
- Protein Simple- Ella™
- MSD Quickplex*
- Aushon Cira*
- Singulex Erenna
- Randox Evidence Investigator*
- Synergy H4
- LI-COR Odyssey
*multiplex capabilities
Automated
- Roche Cobas e411 (immunoassay)
- Roche Cobas c501 (clinical chemistry)
- DPC Immulite (immunoassay)
Methods
- ELISA (EIA)
- RIA (Radioimmunoassay)
- Ultracentrifugation
- Precipitation
From the Pacific
Biomarkers Library:
Association of Apolipoprotein B and Nuclear Magnetic Resonance Spectroscopy-Derived LDL Particle Number with Outcomes in 25 Clinical Studies
The Value of Client Team
Each client team at Pacific Biomarkers incorporates experience from expert scientists, business managers and project services. This team collaborates with a sponsor to provide preanalytical oversight, an innovative menu and exceptional services through direct scientific and technical consultation. Efficient timelines are maintained and optimal outcomes are provided to achieve drug product differentiation for the client.
Read more on how our team approach can work for you
Did You Know?
Nearly 30 million people battle diabetes and every 23 seconds someone new is diagnosed. Diabetes causes more deaths a year than breast cancer and AIDS combined.
Over the last several years, Pacific Biomarkers has actively supported the American Diabetes Association, donating over $31,000 in 5 years. In 2015, we ranked #3 in corporate philanthropy for the ADA.